CSL Behring Acquires AMT-061, Hem B Gene Therapy in Phase 3 Trial

CSL Behring Acquires AMT-061, Hem B Gene Therapy in Phase 3 Trial

293877

CSL Behring Acquires AMT-061, Hem B Gene Therapy in Phase 3 Trial

CSL Behring has closed an agreement giving it global commercialization and licensing rights to AMT-061, an experimental gene therapy for hemophilia B now being tested in a Phase 3 clinical trial. The therapy’s developer, uniQure, will receive an upfront cash payment of $450 million from CSL Behring and is eligible for additional royalty payments, as well as up to $1.6 billion if certain regulatory and commercial milestones are met. uniQure remains responsible for completing the ongoing Phase…

You must be logged in to read/download the full post.